Analyzing R&D Budgets: Gilead Sciences, Inc. vs Veracyte, Inc.

Biotech R&D: Gilead vs. Veracyte's Decade of Innovation

__timestamp	Gilead Sciences, Inc.	Veracyte, Inc.
Wednesday, January 1, 2014	2854000000	9804000
Thursday, January 1, 2015	3014000000	12796000
Friday, January 1, 2016	5098000000	15324000
Sunday, January 1, 2017	3734000000	13881000
Monday, January 1, 2018	5018000000	14820000
Tuesday, January 1, 2019	9106000000	14851000
Wednesday, January 1, 2020	5039000000	17204000
Friday, January 1, 2021	5363000000	29843000
Saturday, January 1, 2022	4977000000	40603000
Sunday, January 1, 2023	6923000000	57305000
Monday, January 1, 2024	5907000000

Unveiling the hidden dimensions of data

A Decade of Innovation: R&D Spending in Biotech

In the ever-evolving world of biotechnology, research and development (R&D) are the lifeblood of innovation. Over the past decade, Gilead Sciences, Inc. and Veracyte, Inc. have demonstrated contrasting approaches to R&D investment. Gilead Sciences, a giant in the biotech industry, has consistently allocated substantial resources to R&D, with expenditures peaking at approximately $9.1 billion in 2019. This represents a staggering 220% increase from their 2014 spending. In contrast, Veracyte, Inc., a smaller player, has shown a more modest yet steady growth in R&D investment, with a notable 484% increase from 2014 to 2023. By 2023, Veracyte's R&D budget reached around $57 million. These figures highlight the diverse strategies within the biotech sector, where both giants and emerging companies strive to innovate and lead in their respective niches.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025